Key result
Azacitidine is linked to pericarditis in three patients with myelodysplastic syndrome or acute myeloid leukemia.
Why the study?
Azacitidine administration has been associated with pericarditis, but detailed case descriptions and recognition of this adverse reaction are limited.
Does azacitidine administration cause pericarditis in patients with high-grade myelodysplastic syndrome or acute myeloid leukemia?
Case Report (n=3)
No
Does azacitidine administration cause pericarditis in patients with high-grade myelodysplastic syndrome or acute myeloid leukemia?
Azacitidine administration may be associated with the development of pericarditis, a potential cardiotoxic adverse effect that responds to corticosteroids.
May prompt vigilance for pericarditis with azacitidine in MDS/AML; case reports leave open causality and generalizability.
STUDY OBJECTIVE: To describe three cases of pericarditis probably related to azacitidine administration in a span of 3 years at our center. DESIGN: Case series. SETTING: Comprehensive cancer center within a large, academic medical center. PATIENTS: Three patients with high-grade myelodysplastic syndrome or acute myeloid leukemia who received azacitidine. INTERVENTION: None. MEASUREMENTS: None. MAIN RESULTS: Patient 1 presented with pericarditis after cycle 2 of azacitidine, patient 3 presented 3 weeks after completing cycle 5, and patient 2 presented during cycle 1. All patients were treated symptomatically and responded to corticosteroids. None of the patients were re-challenged with hypomethylating agents. Use of the Naranjo adverse drug reaction probability scale indicated a probable adverse drug reaction (score of 6) for patients 1 and 3 and a possible adverse drug reaction (score of 3) for patient 2. CONCLUSION: With the exclusion of other common causes of pericarditis, we believe it is likely that azacitidine was responsible for the findings in our patients. Providers caring for patients receiving hypomethylating agents should consider this potential adverse drug reaction in the setting of unexplained chest pain or other clinical signs consistent with cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Newman et al. (2016) conducted a case report in high-grade myelodysplastic syndrome or acute myeloid leukemia (n=3). Azacitidine was evaluated on Pericarditis. Azacitidine administration was identified as a probable or possible cause of pericarditis in three patients with myelodysplastic syndrome or acute myeloid leukemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: